Analysis

Mid-Day Market Update: Vince Holding Surges After Q2 Results; Ritter Pharmaceuticals Shares Slide

Midway through trading Friday, the Dow traded up 0.21% to 27240.50 while the NASDAQ rose 0.09% to 8201.68. The S&P also rose, gaining 0.16% to 3,014.30.

Leading and Lagging Sectors

Materials shares climbed 1% on Friday. Meanwhile, top gainers in the sector included AgroFresh Solutions, Inc. AGFS 5.58%, up 5%, and Taseko Mines Limited TGB 9.69%, up 5%.

In trading on Friday, consumer staples shares fell 0.4%.

Top Headline

Castle Creek Pharmaceutical Holdings announced it will acquire Fibrocell Science, Inc. FCSC 59.56%, a cell and gene therapy company in a $3 per share cash.

Castle Creek Pharmaceuticals is a privately held company developing therapies for patients with rare, serious or debilitating dermatologic conditions. Castle Creek Pharmaceuticals already has a licensing and development collaboration with Fibrocell, which began in April.

Equities Trading UP

MER Telemanagement Solutions Ltd. MTSL 34.17% shares shot up 41% to $1.69 after reporting half-year results. Mer Telemanagement reported H1'19 EPS of $(0.04) on sales of $2.6 million.

Shares of Fibrocell Science Inc FCSC 59.56% got a boost, shooting up 60% to $2.93 after the company agreed to be acquired by Castle Creek Pharmaceutical for an all-cash consideration of $3 per share.

Vince Holding Corp. VNCE 26.91% shares were also up, gaining 23% to $14.12 after the company reported Q2 results.

Equities Trading DOWN

Ardelyx, Inc. ARDX 16.24% shares tumbled 12% to $5.52. Ardelyx announced the FDA has approved its tenapanor, brand name Ibsrela, a 50mg twice-daily oral pill for the treatment of irritable bowel syndrome with constipation in adults. The drug acts locally in the gastrointestinal tract by inhibiting the sodium-hydrogen exchanger, leading to increased bowel movements and decreased abdominal pain.

Shares of Park City Group, Inc. PCYG 12.94% were down 16% to $6.45 after reporting Q4 results.

Ritter Pharmaceuticals, Inc. RTTR 70.73% was down, falling 71% to $0.3148 following a clinical readout. Ritter said the Phase 3 trial of RP-G28 that's being evaluated for lactose intolerance failed to show statistical significance in its pre-specified primary endpoint..

Commodities

In commodity news, oil traded down 0.1% to $55.02, while gold traded down 0.2% to $1,504.40.

Silver traded down 1.4% Friday to $17.925, while copper rose 2.3% to $2.7005.

Euro zone

European shares were higher today. The eurozone’s STOXX 600 rose 0.28%, the Spanish Ibex Index rose 0.5%, while Italy’s FTSE MIB Index rose 0.37%. Meanwhile, the German DAX rose 0.5% and the French CAC 40 climbed 0.3% while UK shares rose 0.3%.

Economics

The import price index dropped 0.5% for August, while export prices declined 0.6% last month.

U.S. retail sales increased 0.4% for August, versus economists’ expectations for a 0.2% rise.

The University of Michigan's consumer sentiment index rose to 92 in September, versus 89.8 in previous month.

U.S. business inventories rose 0.4% for July, versus economists’ expectations for a 0.3% gain.

The Baker Hughes North American rig count report for the latest week is schedule for release at 1:00 p.m. ET.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.